ERIN MARLER: Open Payments
NPI 1326765116 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,248 in 51 payments from 19 companies in 2025. Trend: 2023 $169 · 2024 $957 · 2025 $1,248
Food & beverage: $1,126Education: $122
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $193 |
| Janssen Biotech, Inc. | 6 | $182 |
| ABBVIE INC. | 7 | $165 |
| Incyte Corporation | 4 | $153 |
| Daiichi Sankyo Inc. | 4 | $94 |
| PFIZER INC. | 2 | $62 |
| GlaxoSmithKline, LLC. | 3 | $57 |
| BeOne Medicines USA, Inc. | 2 | $50 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
Products named: VENCLEXTA, RYBREVANT, Enhertu, SCEMBLIX, KISQALI, IBRANCE, TEVIMBRA, KEYTRUDA.
Industry payments across VA — which companies pay providers there.
